This company has been quietly innovating the way infectious diseases are diagnosed and is set to tap into a multi-billion dollar industry demand. With only 2% of the Australian market, the company took in almost $2M in revenue with a 92% compound annual growth rate. So what is it worth if it moves to 10% of the Australian market and starts picking up US sales too?
What if it starts to get toward 2% of the US market in the next year or so? That might mean a revenue in the order of $10M plus. This is a future $300m market cap company that is just starting to book revenue, increase sales, increase products, increase market share.
Time to take an interest in this one.
R
Way undervalued
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
67.5¢ |
Change
-0.015(2.17%) |
Mkt cap ! $155.4M | |||
| Open | High | Low | Value | Volume |
| 68.5¢ | 68.5¢ | 67.5¢ | $8.27K | 12.21K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34322 | 67.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 68.5¢ | 7757 | 1 |
View Market Depth
| Last trade - 13.57pm 29/11/2024 (20 minute delay) ? |
| GSS (ASX) Chart |
